CHROMOSOME 22

Overview of the Chromosome
The link between abnormalities in the long arm of chromosome 22 (that is, 22q) and meningiomas was first suspected in patients with NF2. The hallmark of this disease is bilateral acoustic schwannomas as well as meningiomas (occurring in ~ 50% of patients).
27 Cytogenetic and molecular studies have culminated in the discovery of the NF2 tumor suppressor gene, located on chromosome 22q12.1, and its protein product (that is, schwannomin or merlin). 11, 26, 42, 47, 79, 89, 91 An NF2-associated meningioma is relatively rare, however, because the majority of these lesions occur as isolated, sporadic tumors. Nevertheless, deletions of chromosome 22 are found in all NF2-associated meningiomas, and in 54 to 78% of sporadic meningiomas. 8, 19, 20, 25, 46, 53, 54, 56, 59, 79, 89, [92] [93] [94] Further analysis of the NF2 gene in sporadic meningiomas reveals that approximately one third to one half of these tumors have an inactivating mutation, often accompanied by loss of the other allele. 42, 46, 73 Thus, the frequency of LOH of chromosome 22 exceeds that of NF2 gene abnormalities, with deletion mapping showing interstitial deletions not including the NF2 locus in some meningiomas. 73 This discrepancy between the higher incidence of chromosome 22 LOH and the lower frequency of NF2 gene mutations has led to the search for a second tumor suppressor gene on 22q, in proximity to but distinct from the NF2 gene. 2, 20, 26, 43, 44, 68, 72, 73, 78 These studies have resulted in other possible candidates, including the BAM22, LARGE, MN1, and INI1 genes ( Table 2 and Fig. 4) . 45, 65, 66, 76 Chromosome 22q
The NF2 Gene. The NF2 gene codes for the schwannomin/merlin protein (also known as moesin-, ezrin-, radixinlike protein), which is a part of the band 4.1 families of cytoskeleton-associated proteins (Table 2) . Small insertions or deletions of this gene produce nonsense mutations resulting in a nonfunctional merlin protein. 50 Loss of the merlin protein results in decreased cell adhesion and tumorigenesis.
24,32 A reduced expression of schwannomin/merlin has been demonstrated in sporadic meningiomas. 41 Interestingly, meningioma subtypes show differences in their frequency of NF2 gene mutation. The most common meningioma subtypes are fibrous, transitional, and meningothelial (Table  1) . Although these World Health Organization Grade I subtypes show no difference in their recurrence rates, there are differences in their rates of NF2 mutations. Fibroblastic and transitional meningiomas exhibit NF2 gene mutations in 70 to 80% of tumors, whereas the meningothelial subtype shows NF2 mutations only 25% of the time, suggesting that cytogenetic differences in the tumorigenesis of meningioma subtypes may exist. 89 In both atypical and anaplastic meningiomas the frequency of NF2 gene mutations is approximately 70%, a frequency closely matching the mutation rate in fibroblastic and transitional meningiomas. 41 Therefore, NF2 gene mutations are probably involved with tumorigenesis but not tumor progression. Recent in vivo experiments in mice support this theory. Biallelic NF2 inactivation of mouse leptomeningeal cells by using Cre-mediated molecular techniques resulted in the development of meningiomas in approximately one third of mice studied. 34 This supports the proposition that merlin loss alone is not sufficient for meningioma development.
The BAM22 Gene. The BAM22 gene on chromosome 22q12 is a member of the human ␤-adaptin gene family. The BAM22 gene was cloned from a homozygous deletion on one meningioma. 65 Further analysis revealed that inactivation of the BAM22 gene occurred in nine (12.7%) of 71 sporadic meningiomas, with both the BAM22 and NF2 genes affected in two lesions. Although the function of the BAM22 protein is unknown, its similarity to members of the ␤-adaptin family indicates that it may have a role in intracellular transport of proteins in the trans-Golgi network.
The LARGE Gene. The LARGE gene was identified in the 22q12.3-q13.1 region as a possible meningioma tumor suppressor gene candidate by applying LOH studies. Gene cloning of this segment characterized a protein that is structurally similar to members of the N-acetylglucosaminyltransferase family. Glycosyltransferase enzymes synthesize glycoprotein and glycosphingolipid sugar chains within different compartments of the Golgi network. Evidence of a role for glycosyltransferase enzymes in tumorigenesis exists (for example, various growth factor receptors appear to be regulated by gangliosides). 66 Specifically, meningioma tumor samples can be divided into ganglioside GD3-normal and GD3-rich groups. Furthermore, monosomy 22 correlates with GD3 content, and meningiomas with monosomy 22 show a greater likelihood of recurrence. Therefore, the LARGE gene is implicated in meningioma tumorigenesis because of its location on chromosome 22, but no evidence exists to implicate this gene directly. The MN1 Gene. Analysis of a patient with multiple meningiomas revealed a missing region on chromosome 22 that encodes for the MN1 gene. 45 Further analysis of this tumor showed an absence of the MN1 protein with an intact NF2 gene, suggesting a possible role for the MN1 protein in tumor suppression. The function of the MN1 protein is unknown, although based on its amino acid structure, it most likely plays a role in transcription.
The INI1 22q and was analyzed for mutations in 126 meningiomas. The analysis showed that four (3%) of 126 exhibited an identical mutation in exon 9. The function of the INI1 protein is unknown, but its structure suggests that it functions in transcriptional regulation by remodeling chromatin in an adenosine 5Ј-triphosphate-dependent fashion.
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CHROMOSOME 1
Deletions of the short arm of chromosome 1 are the second most frequent alteration detected on cytogenetic analysis of meningiomas (after chromosome 22 anomalies). 9 According to FISH studies showing monosomy 1p in 70% of atypical and almost 100% of anaplastic meningiomas, this indicates a correlation between loss of chromosome 1p and meningioma progression. 31, 55, 84, 92 Loss of 1p also correlates with tumor recurrence; the rate of recurrence is 30% with loss of 1p but only 4.3% when 1p is retained. 37 It is unknown which gene on the 1p arm results in the clinical effects on tumor, but research has identified alkaline phosphatase as a possible tumor suppressor 37, 92 whose location on chromosome 1p (1p34¡1p36.1) and loss of function is correlated with higher-grade meningiomas.
OTHER CHROMOSOMAL ABNORMALITIES
IDENTIFIED IN MENINGIOMAS Many cytogenetic alterations are associated with meningioma progression and typical or anaplastic histology, including the presence of dicentric or ring chromosomes; losses of chromosome arms 1p, 6q, 7, 9p, 10, 14q, 18q, 19, or 20; as well as gains/amplifications of 1q, 9q, 12q, 15q, 17q, or 20q (Figs. 2 and 3A) . 3, 14, 16, 17, 35, 39, 42, 58, 67, 77, 80, 85, 88 The mechanisms by which these losses and gains aid tumor progression are unknown, although several chromosomes and genes appear to have specific associations with benign, atypical, and anaplastic meningioma grades. Benign meningiomas are more liable to have 14q deletions. 16 Approximately two thirds of anaplastic meningiomas exhibit altered cell-cycle checkpoint tumor suppressor genes located on chromosome 9p, including CDKN2A (p16
INK4a
), p14 ARF , and CDKN2B (p15
INK4b
).
14,57 Further evidence implicating CDKN2A deletions in meningioma pathogenesis comes from the significantly shorter survival times of patients with this deletion, compared with those of patients without it. 60 The membrane-associated 4.1 protein family DAL-1 (differently expressed in adenocarcinoma of the lung), located on chromosome 18p11.3, has been suggested as a tumor suppressor.
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Other rare molecular abnormalities include PTEN gene deletion (10q23), CDKN2C gene deletion (1p32), and RPS 6KB1 gene amplification (17q23). 14, 16, 17, 64 No specific tumor suppressor genes associated with meningiomas have been elucidated on chromosome 7. Nevertheless, two growth factors often implicated in meningioma growth and development, epidermal growth factor receptor and insulin-like growth factor-II are located on chromosome 7.
12,90 Cytogenetic alterations can also include changes in chromosome number. Sixty percent of meningiomas have been found to be hypodiploid, 33% diploid, 4.5% hyperdiploid, and 2.5% hypotriploid. 52 Complex karyotypes with hypodiploidy, structural rearrangements such as ring chromosomes, dicentrics, double minutes, and association between satellites seem to be associated with aggressive tumor characteristics. 48, 49 Identification of a microsatellite instability phenotype in meningiomas has also been described.
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ONCOGENE EXPRESSION IN MENINGIOMAS
Several studies have shown increased expression of oncogenes in meningioma tumorigenesis. Human meningiomas are marked by enhanced expression of the c-sis and cmyc oncogenes. 13, 36, 82 Similarly, the rare Ha-ras and c-mos oncogenes have a higher activation in individuals with intracranial tumors, including meningiomas, than in healthy patients.
18,23 It has been proposed that the nuclear transcription-regulating genes c-myc and c-fos are normally under the control of tumor suppressor genes, which are lost in meningiomas. 22 This is supported by the greater than 70% occurrence of protooncogene messenger RNA expression for c-myc and c-fos in meningiomas. Mutation in the tumor suppressor gene TP53 has been considered a reliable marker for malignant transformation of meningioma, 87 and the bcl-2 protooncogene is also correlated with higher-grade 1 Furthermore, expression of the ROS1 oncogene for tyrosine receptor kinase is common in meningiomas, which indicates that it may play a role in the origin of these tumors. 96 Although no single oncogene has been directly implicated in meningioma development, it is possible that either one or multiple oncogenes mentioned earlier will contribute to this process.
MENINGIOMA CLONALITY
Evidence to support the idea that meningiomas are monoclonal in origin is based on X-chromosome inactivation studies and the observation that most meningiomas have only a single NF2 gene mutation. 33 Polymerase chain reaction evidence suggests, however, that a small number of meningiomas may be polyclonal in origin. 97 In regard to multiple meningiomas, X-chromosomal analysis and mutational NF2 gene analysis suggest that multiple tumors are monoclonal in origin, 40, 83 supporting dural dissemination through the subarachnoid space. 86 Nevertheless, approximately 50% of multiple meningiomas exhibit different NF2 gene mutations, indicating independent tumorigenesis origins.
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SPECIAL SITUATION MENINGIOMAS
The NF2-Associated Meningiomas
The NF2-associated meningiomas comprise 1% of all these lesions, 62 but within the population of patients with NF2, meningiomas are the second most frequent tumor, after vestibular schwannomas. The incidence of meningiomas within this population of patients is between 53 and 83%. 27 Higher proliferative indices and histological grades have been reported by some, whereas others have stated that NF2-associated meningiomas are no more aggressive than sporadic tumors. In general, childhood meningiomas are more likely to be associated with NF2, warranting careful examination for NF2 stigmata. 63 Loss of function of the NF2 gene is generally thought to be the major contributing factor to meningioma development in these patients, as described earlier.
Pediatric Meningiomas
Pediatric meningiomas represent less than 2% of all meningiomas and less than 3% of childhood brain tumors, and occur most commonly in the second decade of life. 62 Unique features of pediatric meningiomas include a higher incidence of intraventricular locations, cystic changes on imaging, lack of dural attachment, and lack of female predilection. 38, 62 Genetically, when compared with adult sporadic meningiomas, pediatric meningiomas have a higher frequency of NF2 gene mutations as well as 1p and 14q deletions. 10, 62, 81 In one study structural abnormalities of chromosome 6 were identified in four of eight cases. 10 Finally, pediatric meningiomas are reported to display more aggressive characteristics.
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Radiation-Induced Meningiomas
A radiation-induced meningioma is one that occurs within a previously irradiated field, is histologically different from the original tumor, appears after a period of time has elapsed since irradiation (usually Ն 5 years), does not occur in a patient with a family history of phakomatosis, and was not present before radiation therapy was administered. 95 Compared with sporadic meningiomas, radiation-induced lesions occur in patients of a young age at presentation and have a higher incidence of multiple tumors, a higher malignancy rate, and a higher recurrence rate after treatment with either surgery or radiation. 4 Although approximately two thirds of sporadic meningiomas occur in women, radiationinduced meningiomas appear to have an equal male/female ratio or even a male predominance. 5 Most patients with postradiation meningiomas were exposed during childhood (for example, cranial radiation therapy for the treatment of leukemia, lymphoma, or craniopharyngioma). 5, 74, 75, 83 For example, in Israel during the 1950s, it was common practice to expose children to low-dose radiation to treat scalp tinea capitis, resulting in a significantly increased incidence of meningiomas once these patients became adults. 71, 74 The estimated relative risk for development of a meningioma is 10-fold greater after exposure to low-dose radiation therapy in childhood. 74 The mean latency period for radiation-induced meningiomas is between 11 and 43 years after exposure. 5, 95 Radiation-induced meningiomas usually exhibit a com- plex karyotype at presentation (that is, the presence of multiple chromosomal arrangements). 5, 95 Unlike sporadic meningiomas, in radiation-induced lesions NF2 gene inactivation and loss of chromosome 22 are less frequent, with LOH in chromosome 22 occurring in 29 to 56% of cases, compared with 43 to 80% of tumors displaying a loss or translocation of 22q. 5, 21 The most frequent cytogenetic abnormalities are found on chromosomes 1p (57-89%), 6q (67%), and 22 (29-58%). 5, 95 A study of six radiation-induced meningiomas discovered the same chromosomal abnormality on the region of 1p13, implicating an unknown gene in this region in the pathogenesis of radiation-induced meningiomas.
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CONCLUSIONS
Chromosomal abnormalities have been detected along with meningioma development in numerous studies using Giemsa staining, FISH, comparative genomic hybridization, and spectral karyotyping techniques. The LOH of chromosome 22 occurs in approximately 60% of meningiomas and loss of NF2 gene function is found in approximately 33%, but abnormalities in other chromosomes and genes have also been implicated. Sporadic, NF2-associated, pediatric, and radiation-induced meningiomas are recognized as potentially having various genetic differences. Further research into how meningioma tumorigenesis and development are affected by the numerous reported irregularities will be necessary to exploit successful new treatments. 
